Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cutaneous vasculitis associated with rifampin therapy.

J P Iredale1, R Sankaran, C G Wathen

  • 1Department of Respiratory Medicine, Rayne Laboratory, City Hospital, Edinburgh, Scotland.

Chest
|July 1, 1989
PubMed
Summary

Rifampin therapy can cause immune complex-mediated cutaneous vasculitis, a rare drug reaction. This case highlights the importance of recognizing this adverse effect in patients receiving rifampin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A challenging case of hypercapnic respiratory failure during pregnancy.

Obstetric medicine·2021
Same author

Resolving the fibrotic niche of human liver cirrhosis at single-cell level.

Nature·2019
Same author

Prevalence of Enterotoxigenic Staphylococci in Bakery Products.

Journal of food protection·2019
Same author

αv integrins on mesenchymal cells regulate skeletal and cardiac muscle fibrosis.

Nature communications·2017
Same author

MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation.

Mucosal immunology·2017
Same author

Overexpression of human kynurenine-3-monooxygenase protects against 3-hydroxykynurenine-mediated apoptosis through bidirectional nonlinear feedback.

Cell death & disease·2016

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Immune complex-mediated vasculitis is a known idiosyncratic drug reaction.
  • Cutaneous vasculitis presents as inflammation of skin blood vessels.

Observation:

  • A patient developed cutaneous vasculitis during rifampin (rifampicin) therapy.
  • This specific association has not been previously documented in medical literature.

Findings:

  • Rifampin therapy was associated with the development of immune complex-mediated cutaneous vasculitis.
  • This represents a previously unreported adverse drug reaction to rifampin.

Implications:

  • Clinicians should consider rifampin as a potential cause of cutaneous vasculitis.
  • Increased awareness of this adverse effect is crucial for patient safety and timely diagnosis.

Related Experiment Videos